Clinical Trial Results:
Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppressed HIV infection: A randomized open-label superiority trial. The AVERTAS-1 trial
Summary
|
|
EudraCT number |
2019-004999-19 |
Trial protocol |
DK |
Global end of trial date |
06 Nov 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Apr 2025
|
First version publication date |
12 Apr 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
191001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Department of Infectious Diseaess, Copenhagen University Hospital - Amager and Hvidovre
|
||
Sponsor organisation address |
Kettegaard Alle 30, Hvidovre, Denmark, 2650
|
||
Public contact |
Karen Brorup Heje Pedersen, Department of Infectious Diseaess, Copenhagen University Hospital - Amager and Hvidovre, +45 38626061, karen.brorup.heje.pedersen@regionh.dk
|
||
Scientific contact |
Karen Brorup Heje Pedersen, Department of Infectious Diseaess, Copenhagen University Hospital - Amager and Hvidovre
, +45 38626061, karen.brorup.heje.pedersen@regionh.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
02 Jan 2024
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
06 Nov 2023
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
06 Nov 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The aim of this study is to investigate if discontinuing abacavir by switching from a 3 drug regimen with with dolutegravir /abacavir/lamivudine to a 2 drug regimen with dolutegravir/lamivudine will cause changes in weight, and in metabolic and cardiac parameters in individuals infected with HIV.
|
||
Protection of trial subjects |
Plasma HIV-RNA
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
05 Oct 2020
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 81
|
||
Worldwide total number of subjects |
81
|
||
EEA total number of subjects |
81
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
77
|
||
From 65 to 84 years |
4
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
Participants were screened and recruited from the outpatient clinics at the Departments of Infectious Diseases at Copenhagen University Hospital - Amager and Hvidovre and Rigshospitalet from October 2020 to November 2022. | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Inclusion cirteria: ≥ 18 years; DTG/ABC/3TC treatment for at least 6 months; Female participant: Contraception during study period Exclusion criteria: pre-existing resistance to 3TC or DTG, hepatitis B antigen (HBsAg) or HBV DNA, cancer within the past five years, unstable cardiovascular disease or diabetes, pregnancy/breastfeeding. | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Baseline (overall period)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
DTG/3TC | ||||||||||||||||||||||||
Arm description |
Intervention arm, switched treatment to dolutegravir (DTG) + lamivudine (3TC) | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
dolutegravir/lamivudine
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
co-formulated DTG 50 mg and 3TC 300 mg administrated once daily
|
||||||||||||||||||||||||
Arm title
|
DTG/ABC/3TC | ||||||||||||||||||||||||
Arm description |
Continued treatment with dolutegravir (DTG)/abacavir(ABC)/lamivudine(3TC) | ||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||
Investigational medicinal product name |
dolutegravir/abacavir/lamivudine
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
co-formulated dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg administrated once daily.
|
||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
DTG/3TC
|
||
Reporting group description |
Intervention arm, switched treatment to dolutegravir (DTG) + lamivudine (3TC) | ||
Reporting group title |
DTG/ABC/3TC
|
||
Reporting group description |
Continued treatment with dolutegravir (DTG)/abacavir(ABC)/lamivudine(3TC) |
|
|||||||||||||
End point title |
Body weight | ||||||||||||
End point description |
Difference in mean weight from baseline to week 48 between treatment arms
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline to week 48
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Primary endpoint | ||||||||||||
Statistical analysis description |
To analyse repeated measurements, a linear mixed model was employed, comparing changes in weight across treatment arms from baseline to week 24 and week 48, assuming a linear relationship over time.
|
||||||||||||
Comparison groups |
DTG/ABC/3TC v DTG/3TC
|
||||||||||||
Number of subjects included in analysis |
76
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
> 0.05 | ||||||||||||
Method |
Regression, Linear | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Confidence interval |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
October 2020 to november 2023
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
NA
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
DTG/3TC
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Intervention arm, switched treatment to dolutegravir (DTG) + lamivudine (3TC) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
DTG/ABC/3TC
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Continued treatment with dolutegravir (DTG)/abacavir(ABC)/lamivudine(3TC) | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
09 Sep 2020 |
• HIV-RNA and CD4 cell count control changed from to week 1, 4, 24 and 48 (instead of week 1, 4, 12, 24, 36, 48)
• Plasma erythrocyte volume fraction added to blood tests, because it was used in the cardiac MRI analysis
• The questions about adverse effects omitted from questionnaire, because low risk of adverse effects are expected since the participants either continue usual treatment or a reduced regimen with the same drugs.
• 24-hour EKG-monitoring added to the cardiac MR sub study to evaluate potential cardiac arrhythmia
|
||
12 Feb 2021 |
• 24-hour EKG-monitoring added to the cardiac MR sub study to evaluate potential cardiac arrhythmia |
||
23 Apr 2021 |
• Enrolment of healthy controls added to the cardiac MR sub study project
• Specification of cardiac MR sub study outcomes
|
||
24 Aug 2023 |
• Specification of primary endpoint to difference in change from baseline to week 48 between the intervention arm and the control arm (continuous outcome) - Previous wording could be interpret as I binary outcome
• Sample size changed from 95 to 70 participants by downsizing from 90-80%: Due to limited eligible participants in the two study sites
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |